NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

NovaBridge BiosciencesNASDAQ: NBP

Net Change in Cash · Q4 FY2025 · quarter ended Dec 2025

Net change in cash turns negative

Q4 FY2025 net change in cash was -$17.43M, compared with $0 a year earlier. Trailing-twelve-month net change in cash was $446.12M.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$17.43M or moves back toward the trailing-twelve-month quarterly average of $111.53M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$17.43M-103.9% QoQ
Last fiscal yearDec 2025
$142.37M+108.3% YoY
LTMSep 2025
$446.12M— YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+108.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

Mixed currencies · from the cash flow

Latest · FY2025
142.37M USD
Year-over-year change
—

Net Change in Cash vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
NBP Competitors
Net Change in Cash for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBPNovaBridge BiosciencesLTM Sep 2025CN¥446.12M CNY———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$300.86M USD—+123.5%—
ANNXAnnexon, Inc.LTM Mar 2026$78.09M USD+242.4%+20.1%—
ALTAltimmune, Inc.LTM Mar 2026$48.5M USD+262.3%—134713.9%
AURAAura Biosciences, Inc.LTM Mar 2026$46.57M USD+289.8%——
ENGNenGene Holdings Inc.LTM Apr 2026$27.72M USD-86.6%——
GALTGalectin Therapeutics Inc.LTM Mar 2026$6.68M USD+141.4%——
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$2.28M USD+363.2%+743.9%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1M USD-185.5%-61.2%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$897K USD-94.3%-72.4%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$221K USD-101.5%-2.2%—
Peer median (excluding NBP) —+141.4%+8.9%134713.9%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Net Income(2.33B)(2.51B)(208.18M)(362.72M)(88.34M)
Depreciation & Amortization34.14M63.82M1.06M7.14M856K
Deferred Income Tax00000
Stock-Based Compensation608.61M357.15M10.26M(14.23M)5.97M
Change in Working Capital394.52M552.06M(37.2M)(20.52M)17.07M
Accounts Receivables97.42M33.08M000
Inventory(27.24M)27.24M000
Accounts Payables107.85M0000
Other Working Capital216.49M491.75M(37.2M)(20.52M)17.07M
Other Non-Cash Items321.18M431.48M161.2M5.9M43.84M
Operating Cash Flow(973.09M)(1.1B)(72.85M)(384.42M)(20.6M)
Capital Expenditures(29.93M)(45.83M)(164.35K)(350.34K)(7K)
Acquisitions (Net)(6M)0000
Purchases of Investments(10.17B)(7.41B)0(1.79B)(49.96M)
Sales of Investments9.48B7.91B0801.66M154.89M
Other Investing Activities026K(107.47M)452.53K47K
Investing Cash Flow(727.21M)458.38M(107.63M)(992.42M)104.97M
Debt Repayment02.75M000
Common Stock Issued000061.91M
Common Stock Repurchased0(3.08M)(8.66M)(2.45M)0
Dividends Paid00000
Other Financing Activities593.92M60.86M407.88K0(4.19M)
Financing Cash Flow593.92M42.36M(8.25M)(2.44M)57.73M
Effect of Forex Changes(128.77M)389.2M36.89M(327.04M)276K
Net Change in Cash(1.24B)(212.86M)(151.58M)(1.71B)142.37M
Free Cash Flow(1B)(1.15B)(73.02M)(384.77M)(20.6M)

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.